The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients.

• Limited data are available regarding antibody response and the safety of the monovalent influenza A H1N1/09 vaccine for immunocompromised patients. In this study, the humoral response to this vaccine in solid organ transplant (SOT) recipients and healthy individuals was evaluated. Eighty-two SOT recipients and 28 healthy individuals received two doses of the influenza A H1N1/09 AS03 adjuvanted vaccine containing 3.75mg of haemagglutinin at a 3- to 4-week interval. Serum samples were drawn at baseline and 3-4weeks after the first and second vaccine doses. Seroprotective titres were measured with a haemagglutination inhibition. After the first dose seroprotective titres were observed in 69% of the SOT patients and in 96% of the healthy controls (P=0.006), and increased after the second dose to 80% and 100%, respectively (P=0.003). All controls and 77% of the SOT recipients achieved a ≥4-fold titre rise after the first immunisation (P=0.005). The vaccine was well tolerated and no acute rejection was observed. Influenza A H1N1/09 vaccine elicited a protective antibody response in the majority of SOT recipients, but the response was lower when compared with controls. A second dose significantly improved vaccine immunogenicity in SOT recipients. (ClinicalTrials.gov number: NCT01254955).

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

Adult

Aged

Aged

80 and over

Antibodies

Viral

blood

Glomerular Filtration Rate

Humans

Influenza A Virus

H1N1 Subtype

immunology

Influenza Vaccines

immunology

Influenza

Human

epidemiology

Middle Aged

Organ Transplantation

Pandemics

Time Factors

Vaccination

Publication and Content Type

ref (subject category)

art (subject category)